Infliximab for Ocular Behçet’s Syndrome
Infliximab can be used for the treatment of ocular manifestations of Behçet’s disease. [1]
Guideline-Based Use
The American Uveitis Society expert panel recommendations state that infliximab (along with adalimumab) can be considered as a first-line immunomodulatory agent for ocular manifestations of Behçet’s disease. (Recommendation level not specified in the source abstract.) [1]
Clinical Scope
This recommendation is specifically for ocular involvement (eg, sight-threatening uveitis), where anti–TNF-α therapy is used as immunomodulatory treatment. [1]
Practical Clinical Positioning
Infliximab is considered for patients with severe ocular inflammatory disease requiring immunomodulation, including cases where standard therapies are inadequate or not feasible. [1]
Safety and Monitoring Considerations
Infliximab use should occur within immunomodulatory care and includes standard anti–TNF-α risk assessment and monitoring practices for serious infection and other adverse effects. [1]